Rami Levin - 14 Aug 2026 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: CEO and President
Issuer ticker: CNSP
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 09:00:03 UTC
Prior SEC filing: 02 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Rami Levin

Key filing fact

Rami Levin filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 18 Aug 2026.

Key facts

This page summarizes Rami Levin's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2026, 09:00.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002102719 Primary reporting owner

Levin Rami

Relationship: CEO and President
Address: C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON
Signature: /s/ Rami Levin
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNSP transaction

Common Stock

Options Exercise

Transaction value
Shares: -4,750
Change %: -50%
Price: $0.000000^*
Shares after: 4,750
Date: 14 Aug 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -4,750
Change %: -25%
Price: $0.000000^*
Shares after: 14,250
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,750
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Footnote F2

On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

Footnote F3

Issued in connection with the reporting person's employment with the Company.